AB-343

AB-343 is a selective covalent inhibitor of SARS-CoV-2 Mpro, with an IC50 of 8 nM and a Ki of 2.8 nM. AB-343 can effectively inhibit the main proteases of SARS-CoV-2 and many other coronaviruses, and is also active against some resistant variants. AB-343 can be used in the research of treating coronavirus infection-related diseases[1][2].

Product Specifications

CAS Number

[3077209-48-1]

UNSPSC

12352005

Target

SARS-CoV; Virus Protease

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Smiles

O=C([C@H](NC(C(F)(F)F)=O)CC1CCC1)N2[C@H]3CC[C@@H]([C@H]2C(N[C@H](C#N)C[C@H]4CC(C)(NC4=O)C)=O)C(F)(F)C3

Molecular Formula

C26H34F5N5O4

Molecular Weight

575.57

References & Citations

[1]McGovern-Gooch KR, et al. Biological characterization of AB-343, a novel and potent SARS-CoV-2 Mpro inhibitor with pan-coronavirus activity. Antiviral Res. 2024 Dec;232:106038.|[2]Mason J D, et al. Development of a Scalable Manufacturing Process for AB-343 Drug Substance: A Potential Candidate for the Treatment of Coronavirus Infections. Organic Process Research & Development, 2025.